Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 18/20 | 0.62 |
| ▸ | RARA | P10276 | 1/20 | 0.62 |
| ▸ | RARB | P10826 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | RARG | P13631 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2086735 | 1.00 | GCK (0.62) | GCKRARARARBLMNAHPGD | |
| SCHEMBL1107685 | 1.00 | GCK (0.62) | GCKRARARARBLMNAHPGD | |
| SCHEMBL2085174 | 0.90 | GCK (0.68) | GCKRARARARBRARG | |
| SCHEMBL1107730 | 0.90 | GCK (0.68) | GCKRARARARBRARG | |
| SCHEMBL1107456 | 0.90 | GCK (0.68) | GCKRARARARBRARG | |
| SCHEMBL2084645 | 0.90 | GCK (0.59) | GCKRARARARBLMNAHPGD | |
| SCHEMBL2662217 | 0.89 | LMNA (0.54) | GCKRARARARBLMNAHPGD | |
| SCHEMBL1427108 | 0.89 | LMNA (0.54) | GCKRARARARBLMNAHPGD | |
| SCHEMBL1042436 | 0.89 | LMNA (0.54) | GCKRARARARBLMNAHPGD | |
| SCHEMBL1140707 | 0.88 | GCK (0.61) | GCKRARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059522-B1 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-08 | — | — | EP | disclosed |
| EP-2197849-B1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2013-02-27 | — | — | EP | disclosed |
| EP-2197849-B1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-8236824-B2 | N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-08-07 | — | — | US | disclosed |
| US-8236824-B2 | N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-08-07 | — | — | US | disclosed |
| US-8236824-B2 | N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-08-07 | — | — | US | disclosed |
| US-8222285-B2 | 1,3-dihydroxy substituted phenylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222285-B2 | 1,3-dihydroxy substituted phenylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-20100210690-A1 | N-(PYRAZOLE-3-YL)-BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100179121-A1 | 1,3-DIHYDROXY SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2010-07-15 | — | — | US | disclosed |
| US-20100179121-A1 | 1,3-DIHYDROXY SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2010-07-15 | — | — | US | disclosed |
| EP-2197849-A1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | Merck Patent GmbH (DE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009046802-A1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009046802-A1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008154563-A1 | 1, 3 - DIHYDROXY SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| WO-2008005964-A2 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210690-A1 | N-(PYRAZOLE-3-YL)-BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | GCKR, HK1, GCK | GCK 3/4885RARA 2563/4885RARB 3073/4885 |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | GCK 2/4885RARA 2614/4885RARB 2753/4885 |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | GCK 2/4885RARA 2986/4885RARB 3061/4885 |
| US-20100179121-A1 | 1,3-DIHYDROXY SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | GCKR, GCK, NR4A3 | GCK 2/4885RARA 457/4885RARB 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.